Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
View the full release here: https://www.businesswire.com/news/home/20240531817764/en/
- View the full release here: https://www.businesswire.com/news/home/20240531817764/en/
In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer. - Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.
- HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment.
- “This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.